Biotts, the biopharmaceutical company developing the unique and patented MTC-Y transdermal drug delivery technology, has been granted another patent in the US. The patent covers the MTC-A4 formulation, which has anaesthetic properties and is effective within minutes of application (compared to around 30 minutes for competing products).
Expanding the patent cloud is extremely important from the company’s point of view. It contributes significantly to the value of Biotts. Management is continually working to secure the company’s strategic IP internationally.
The proprietary MTC-Y technology is a truly non-invasive drug delivery alternative. Its properties allow molecules of up to 6,000 Da to be delivered through the skin (compared to 500 Da currently on the market). This makes Biotts a real opportunity for patients who are looking for effective therapies, but who also value comfort and the reduction of treatment side effects (especially from the gastrointestinal tract). Biotts is currently focusing on the development of its diabetology product portfolio, including insulin and semaglutide (patent pending).